PD-1/PD-L1 pathway
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
10
The importance of the PD 1/PD L1 pathway at the maternal fetal interface
12
The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance
9
The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseases
12
PD 1/PD L1 pathway in non small cell lung cancer and its relation with EGFR mutation
6
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
16
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
12
High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers
12
Host expression of PD L1 determines efficacy of PD L1 pathway blockade–mediated tumor regression
12
Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma
11
Autophagy inhibition enhances PD-L1 expression in gastric cancer
14
Macrophage PD L1 strikes back: PD 1/PD L1 interaction drives macrophages toward regulatory subsets
11
Kupffer cells in immune activation and tolerance toward HBV/HCV infection
7
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
5
Oncolytic virus and PD-1/PD-L1 blockade combination therapy
13
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
8
Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors
8
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
10
Targeting PD-1/PD-L1 in lung cancer: current perspectives
16
Immunotherapy in Merkel cell carcinoma: role of Avelumab
5